These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8115415)

  • 41. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
    Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
    Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A dietary haloperidol regimen for inducing dopamine receptor supersensitivity in rats.
    Frey JM; Morgan WW; Ticku MK; Huffman RD
    Pharmacol Biochem Behav; 1987 Apr; 26(4):661-9. PubMed ID: 3602028
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A new animal model of dopamine supersensitivity using s.c. implantation of haloperidol releasing polymers.
    Köhler U; Schröder H; Augustin W; Sabel BA
    Neurosci Lett; 1994 Mar; 170(1):99-102. PubMed ID: 8041522
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lithium dissociates haloperidol-induced behavioral supersensitivity from reduced dopac increase in rat striatum.
    Meller E; Friedman E
    Eur J Pharmacol; 1981 Nov; 76(1):25-9. PubMed ID: 7318921
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Subchronic treatment with haloperidol and clozapine in rats with neonatal excitotoxic hippocampal damage.
    Lipska BK; Weinberger DR
    Neuropsychopharmacology; 1994 May; 10(3):199-205. PubMed ID: 7916917
    [TBL] [Abstract][Full Text] [Related]  

  • 47. D1 and D2 dopamine binding site up-regulation and apomorphine-induced stereotypy.
    Chipkin RE; McQuade RD; Iorio LC
    Pharmacol Biochem Behav; 1987 Dec; 28(4):477-82. PubMed ID: 2893388
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the rat.
    Rupniak NM; Hall MD; Mann S; Fleminger S; Kilpatrick G; Jenner P; Marsden CD
    Biochem Pharmacol; 1985 Aug; 34(15):2755-63. PubMed ID: 4040370
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dopamine receptor changes in response to prolonged treatment with L-dopa.
    Groppetti A; Flauto C; Parati E; Vescovi A; Rusconi L; Parenti M
    J Neural Transm Suppl; 1986; 22():33-45. PubMed ID: 2946813
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neurochemical basis for the absence of overt "stereotyped" behaviors in rats with up-regulated striatal D2 dopamine receptors.
    Fields JZ; Drucker GE; Wichlinski L; Gordon JH
    Clin Neuropharmacol; 1991 Jun; 14(3):199-208. PubMed ID: 1676931
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neuroleptic treatment for a substantial proportion of adult life: behavioural sequelae of 9 months haloperidol administration.
    Waddington JL; Gamble SJ
    Eur J Pharmacol; 1980 Oct; 67(4):363-9. PubMed ID: 7192633
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacological characteristics of dopamine receptors involved in the dual effect of dopamine agonists on yawning behaviour in rats.
    Protais P; Dubuc I; Costentin J
    Eur J Pharmacol; 1983 Oct; 94(3-4):271-80. PubMed ID: 6140175
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serotonin 2A receptor antagonist treatment reduces dopamine D1 receptor-mediated rotational behavior but not L-DOPA-induced abnormal involuntary movements in the unilateral dopamine-depleted rat.
    Taylor JL; Bishop C; Ullrich T; Rice KC; Walker PD
    Neuropharmacology; 2006 May; 50(6):761-8. PubMed ID: 16434065
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serotonergic involvement in haloperidol-induced catalepsy.
    Neal-Beliveau BS; Joyce JN; Lucki I
    J Pharmacol Exp Ther; 1993 Apr; 265(1):207-17. PubMed ID: 8386235
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neuropeptide-dopamine interactions. III. Cyclo(His-Pro) and persistence of dopaminergic supersensitivity on withdrawal from one year continuous neuroleptic treatment.
    Prasad C
    Schizophr Res; 1988; 1(6):411-5. PubMed ID: 2908706
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Concurrent treatment with benztropine and haloperidol attenuates development of behavioral hypersensitivity but not dopamine receptor proliferation.
    Carvey PM; Hitri A; Goetz CG; Tanner CM; Klawans HL
    Life Sci; 1988; 42(22):2207-15. PubMed ID: 3374255
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differential liabilities of haloperidol and thioridazine for inducing apomorphine hypersensitivity.
    De Veaugh-Geiss J; Devanand DP; Carey RJ
    Biol Psychiatry; 1982 Nov; 17(11):1289-301. PubMed ID: 6891268
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
    Hu XT; White FJ
    Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Behavioral responsitivity to dopamine receptor agonists after extensive striatal dopamine lesions during development.
    Neal-Beliveau BS; Joyce JN
    Dev Psychobiol; 1998 May; 32(4):313-26. PubMed ID: 9589220
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Behavioral quantification of striatal dopaminergic supersensitivity after bilateral 6-hydroxydopamine lesions in the mouse.
    Mandel RJ; Wilcox RE; Randall PK
    Pharmacol Biochem Behav; 1992 Feb; 41(2):343-7. PubMed ID: 1574523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.